Image credit: Elouise Gaylard (GRIDD)

New Drugs for the Treatment of Glioblastoma

Glioblastoma is the most common malignant adult primary brain cancer. Median survival is <15 months and only about 10% of patients survive two years without disease recurrence.1 This dismal situation motivates a search for new therapeutic approaches and in particular therapies which target the chemo/radiation-resistant tumour propagating cells, often referred to as glioma stem cells (GSCs).2 This project seeks to synthesise analogues of an exciting natural product that has anti-cancer activity against GSCs and other cancer stem cells (CSCs).3 The compounds will be evaluated as potential drug candidates and certain derivatives could allow mechanism of action and target identification studies.